Retatrutide
Triple GLP-1 / GIP / Glucagon Receptor Agonist
Triple incretin agonist reported to produce 24.2% body-weight reduction at 48 weeks in NEJM Phase 2 data (2023). Available across four vial sizes from 10 mg through 30 mg.
24.2%
Body Wt. Loss
3 (Triple)
Receptors
NEJM 2023
Trial Source
Price
From $134.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
Research protocols typically start at 2mg weekly and escalate in 2mg increments every four weeks up to 8–12mg. The 10mg vial is most often used as a maintenance-tier supply once researchers have titrated through the 2/4/6/8mg steps. Weekly subQ is standard given the ~6-day half-life.
Retatrutide belongs to a third generation of incretin-class research compounds. Where semaglutide targets one receptor (GLP-1) and tirzepatide targets two (GLP-1 plus GIP), retatrutide engages three — adding glucagon-receptor agonism to the combination. The rationale is mechanistic: GLP-1 and GIP reduce appetite and improve insulin response, while glucagon activation drives energy expenditure and hepatic lipolysis. Together, the three signals cover both sides of the energy equation.
Available Sizes
Clinical Trial Evidence
| Trial | Phase 2 — NEJM (2023) |
|---|---|
| Outcome | 24.2% avg. body weight reduction |
| Duration | 48 weeks |
Specifications
| Product | Retatrutide |
|---|---|
| Category | Fat Loss / Metabolic |
| Format | Lyophilized powder |
| Price | From $134.99 |
Reported Endpoints
Triple-receptor mechanism (GLP-1 + GIP + glucagon) adds energy expenditure on top of appetite reduction
Phase-2 NEJM data showed 24.2% body-weight loss at 48 weeks — higher than any prior incretin
Weight-loss curve had not plateaued at trial end, suggesting longer studies may show larger effects
Glucagon-arm activity improves hepatic fat content independently of weight loss
Weekly subcutaneous dosing — the ~6-day half-life supports a 7-day interval
Dose-response is cleaner than the twincretin class in the phase-2 readout
Standard Protocol
Research protocols typically start at 2mg weekly and escalate in 2mg increments every four weeks up to 8–12mg. The 10mg vial is most often used as a maintenance-tier supply once researchers have titrated through the 2/4/6/8mg steps. Weekly subQ is standard given the ~6-day half-life.
Ready to start?
From $134.99
✓ 10% off via PeptidesMuscle
Retatrutide — FAQs
Further Reading
Other Fat Loss / Metabolic Peptides
View All
Mazdutide 6mg
Mazdutide (IBI362) — Innovent Biologics' long-acting GLP-1/glucagon dual agonist, the oxyntomodulin analog licensed from Eli Lilly that received Chinese NMPA approval in 2025 for obesity and T2D.
